# FLARE Team Alignment — September 3, 2026

**Purpose:** Leave the meeting with one agreed Phase II direction and a precise plan for the upcoming potential partner/investor conversation.

## Recommended Position

FLARE should pursue a **staged hybrid path**:

- preserve Phase I as the documented research prototype,
- strengthen the research evidence for publication,
- harden the system toward a controlled pilot,
- seek external mentorship, clinical access, regulatory/compliance guidance, and data partnerships before attempting real-world deployment.

## What We Have Now

Phase I currently demonstrates:

- brain CT abnormality screening,
- 5-class brain MRI classification,
- 2D and 3D MRI segmentation,
- Grad-CAM explainability,
- CT/MRI late decision-level fusion,
- Flask API orchestration,
- React/TypeScript clinician interface,
- Auth0-based login integration,
- EHR-style review workflow,
- prototype regional/outbreak visualization,
- Docker/HPC deployment support.

This is a substantial research prototype. It is not yet a production medical product.

## The Five Decisions We Must Make Tomorrow

### Decision 1 — Direction

Choose one statement:

**Recommended:** "We are pursuing publication-quality validation and pilot readiness in parallel."

Not recommended:

- "We are just finishing senior design."
- "We are ready to sell to hospitals."
- "We are still deciding what FLARE is."

### Decision 2 — Core product hypothesis

Proposed hypothesis:

> FLARE is a clinician-in-the-loop multimodal neuroimaging decision-support platform that combines specialized CT and MRI analysis with explainability, segmentation, and multimodal agreement/disagreement to help clinicians review suspicious brain-imaging cases while producing structured, reviewable data for research and population-level analysis.

The team should decide whether the epidemiology/geo component remains part of the core product or becomes a secondary research module.

### Decision 3 — Biggest technical/research blockers

Recommended top blockers:

1. MRI domain shift / sequence mismatch.
2. Patient-level validation and leakage control.
3. Small tumor-positive-only paired fusion cohort.
4. Lack of paired healthy CT/MRI controls.
5. Need for external clinical validation.
6. Need for deployment/security/data-governance hardening.

### Decision 4 — What we want from the external partner

Do not enter the meeting with a vague request to "help us grow." Ask for concrete leverage.

#### Ask A — Clinical access

- introductions to 1–3 radiologists or imaging specialists,
- feedback on intended use, workflow and output screens,
- recurring clinical advisory sessions if there is mutual interest.

#### Ask B — Data pathway

- guidance or introductions for legitimate paired/same-patient CT + MRI research data,
- help identifying how a university/hospital collaboration would handle IRB, DUA, consent and de-identification,
- access to someone who understands medical imaging data governance.

#### Ask C — Regulatory/product mentorship

- introduction to a medical-device regulatory or digital-health expert,
- help defining what evidence separates a student research prototype from a pilot-ready system,
- advice on what FLARE should not claim yet.

#### Ask D — Infrastructure / technical mentorship

- cloud/MLOps architecture review,
- recommendation for moving from demonstration infrastructure to a controlled pilot environment,
- feedback on model monitoring, auditability and reproducibility.

#### Ask E — Commercialization ecosystem

- introductions to incubators, competitions, university commercialization/IP resources, health-tech accelerators, grant programs or seed-stage mentors,
- advice on when funding is appropriate and what milestones should precede it.

### Decision 5 — 30-day deliverable

Proposed promise:

> Within 30 days, FLARE will deliver a frozen Phase I technical baseline, validated limitations list, updated research plan, fusion evaluation plan, clinical-feedback plan, and production-readiness gap assessment.

Do not promise a hospital deployment in 30 days.

---

# Meeting Flow — 45 Minutes

## 0–5 min — Why we are meeting

Deja:

> "We have a functioning Phase I prototype, but before we meet externally we need to agree on what the next version is trying to become. Today I want us to leave with one direction, the biggest blockers, and exactly what we need from this partner."

## 5–15 min — Technical baseline

Walk through:

- CT model,
- MRI model,
- segmentation,
- Grad-CAM,
- late fusion,
- API,
- frontend,
- clinician review flow.

For every component answer:

- what enters it,
- what comes out,
- which model/technology performs it,
- whether it is validated, prototype-only, or future work.

## 15–25 min — Research weaknesses

Discuss only weaknesses that materially affect credibility:

- domain shift,
- leakage,
- external validation,
- paired controls,
- fusion evidence,
- calibration,
- subgroup analysis.

## 25–35 min — Product/pilot gap

Discuss:

- clinical workflow,
- data governance,
- IRB/DUA,
- DICOM de-identification,
- security,
- deployment,
- regulatory path,
- IP/public repository implications.

## 35–42 min — Partner asks

Pick the **top three asks** the team wants to make. Recommended order:

1. clinical advisor introductions,
2. legitimate data/governance pathway,
3. regulatory/product mentorship.

Infrastructure and funding introductions are valuable secondary asks.

## 42–45 min — Ownership

Every unresolved item gets:

- one owner,
- one deliverable,
- one deadline.

No "the whole team will do it" assignments.

---

# Questions Each Person Should Arrive Ready to Answer

## Everyone

1. Do you support the staged hybrid path?
2. What is FLARE's most important weakness right now?
3. What should be removed or deprioritized?
4. What should FLARE demonstrably accomplish this semester?
5. What workstream will you personally own?

## Research / graduate-program perspective

- Which claims are publication-defensible today?
- Which results must be rerun?
- What comparison would prove that multimodal fusion adds value?
- What venue/research contribution would make the work novel enough to publish?

## Industry perspective

- Which parts look like research code rather than maintainable product code?
- What deployment, testing, security, monitoring or documentation would your company expect before a pilot?
- What would make an engineering team trust this system enough to inherit it?

## Deja / product-lead perspective

- What exactly are we asking the external partner to unlock?
- What can we promise in 30/60/90 days?
- What should remain private until IP/publication ownership is reviewed?
- Which team decisions must happen before the external meeting?

---

# Recommended Partner Opening

> "FLARE started as a senior-design research project and has grown into a working multimodal brain-imaging prototype. We can currently run specialized CT and MRI pipelines, generate explainability and segmentation outputs, fuse paired modality predictions, and present the results through a clinician-facing application. We are not presenting it as a hospital-ready medical product. Our next question is how to validate it correctly and determine whether it has a credible path toward a controlled clinical pilot. We would value your help identifying the right clinical, data, regulatory, and product-development connections to get from this prototype to that next stage."

# What Success From the External Meeting Looks Like

A successful meeting does **not** require receiving money.

Success means leaving with some combination of:

- a named clinician introduction,
- a named medical-data/governance contact,
- a regulatory/product mentor,
- a recommended validation milestone,
- a legitimate data-access path,
- an incubator/funding introduction,
- an agreed follow-up meeting,
- a clear 30-day deliverable he wants to see.

The team should measure the meeting by access, expertise and next actions—not by whether the partner immediately invests.
